Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
17.54 SEK | +1.98% | +5.79% | +13.45% |
04-17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
04-17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Business Summary
Number of employees: 116
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
US Pharma
90.4
%
| 571 | 91.5 % | 578 | 90.4 % | +1.10% |
HQ & Pipeline
9.6
%
| 53 | 8.4 % | 61 | 9.6 % | +16.16% |
Digital Mental Health Programs
0.0
%
| 0 | 0.1 % | 0 | 0.0 % | -75.00% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
90.8
%
| 574 | 92.0 % | 580 | 90.8 % | +0.99% |
European Union
8.6
%
| 46 | 7.3 % | 55 | 8.6 % | +20.61% |
Rest of the World
0.6
%
| 5 | 0.7 % | 4 | 0.6 % | -11.11% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 52 | 30/09/11 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 57 | 31/08/22 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 25/10/22 |
Robert Rönn
CTO | Chief Tech/Sci/R&D Officer | 48 | 31/12/16 |
Cecilia Coupland
COO | Chief Operating Officer | 48 | 31/12/18 |
Lena Wange
IRC | Investor Relations Contact | - | 31/01/16 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 10/04/19 | |
James Noble
CHM | Chairman | 65 | 15/04/20 |
Director/Board Member | 62 | 31/12/01 | |
Michael Matly
BRD | Director/Board Member | 42 | 31/12/21 |
Director/Board Member | 55 | 15/04/20 | |
Christine Rankin
BRD | Director/Board Member | 60 | 31/03/22 |
Robin Evers
BRD | Director/Board Member | - | 26/10/23 |
Director/Board Member | 61 | 10/04/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 842,971 | 0 | 63,000 ( 7.474 %) | 78.49 % |
Stock B | 1 | 34,710,639 | 27,907,534 ( 80.40 %) | 261,044 ( 0.7521 %) |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
OREXO AB 0.85% | 294,866 | 0.85% | 429,643 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Pharmacall AB
Pharmacall AB Investment Banks/BrokersFinance Part of Orexo AB, Pharmacall AB is a Swedish company that provides securities management services. The private company is located in Sweden. |
Investment Banks/Brokers
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.45% | 54.34M | |
+6.14% | 69.91B | |
+12.55% | 9.24B | |
-12.75% | 5.05B | |
+42.38% | 4.47B | |
+5.23% | 3.92B | |
+23.04% | 2.44B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B |
- Stock Market
- Equities
- ORX Stock
- Company Orexo AB